Itacitinib (INCB039110), a JAK1 inhibitor, Reduces Cytokines Associated With Cytokine Release Syndrome Induced by CAR T-Cell Therapy

In a phase I trial, investigators analyzing the effect of blocking JAK pathway signaling on CAR T-cell proliferation, anti-tumor activity, and cytokine levels in in vitro and in vivo models demonstrated that the selective JAK1 inhibitor itacitinib may act prophylactically to prevent CAR T-cell–induced cytokine release syndrome.

Clinical Cancer Research